is the leading company in the emerging field of
Bacterio-Therapeutics.

mycologists h5n1

, Osel, Inc. While a routine
UTI is easily treated with a short course of oral antibiotics, treatment of
recurrent UTI (RUTI ) with multiple courses of antibiotics may lead to
resistant strains, diarrhea, and vaginal yeast infections. Both diseases
result from deficiencies in the normal lactobacillus-dominated microflora
within the reproductive and urinary tracts of susceptible women.

infectious dioxin

We are continuing to
successfully meet our clinical trials milestones for the evaluation of
LACTIN-V for treatment of RUTI and RBV , two conditions which plague 15 million
women a year in the U.
Urinary tract infections (UTI ) account for almost 11 million physician
visits each year in the U. The company's business is based on exploiting recent
scientific discoveries demonstrating the central role of naturally occurring
mucosal bacteria in the maintenance of health and the prevention of disease.gen-probe. Gen-Probe
markets a broad portfolio of products that use the Company's patented
technologies to detect infectious microorganisms, including those causing
sexually transmitted diseases, tuberculosis, strep throat , pneumonia and
fungal infections. In addition, Gen-Probe's TIGRIS
instrument is the only fully automated, high-throughput NAT system for
diagnostics and blood screening.

epidemiologists influenza

About Osel
Osel, Inc. Gen-Probe is headquartered in San Diego and
employs approximately 900 people.

For information about
risks and uncertainties we face and a discussion of our financial statements
and footnotes, see documents we have filed with the SEC, including the Form
10-Q for the quarter ended March 31, 2005, and all subsequent periodic
fillings made with the SEC.

rickettsial nipah

Thus, there is
significant interest amongst women who suffer from RUTI for novel
non-antibiotic therapies.
Osel's mission is to harness the protective properties of these specialized
non-pathogenic bacteria as a basis for a series of innovative products
initially targeted for the prevention and treatment of diseases of the
genitourinary and gastrointestinal tracts.m.

Contact:

Paula Izidoro
Investor Relations
858-410-8904

zoonoses mycobacterial

and Europe," said Osel president, Ralph Levy .
Osel's first product, LACTIN-V, is directed at recurrent urinary tract
infections (RUTI) , and recurrent bacterial vaginosis (RBV). Pacific Time (6:30 p.

h5n1 pathogenic

"We are moving ahead with our business plan to develop products
utilizing naturally occurring mucosal bacteria. Bacterial vaginosis (BV ) afflicts over 16 million
women every year worldwide, and is the most common reason that women seek
medical help, after vaginal yeast infections. LACTIN-V has been optimally
formulated to restore the protective vaginal microflora to combat infections
and is expected to fill this unmet medical need.gen-probe.

Also see specific diseases within the alphabetical listings.

electonic nipah

influenza pathogenic

Eastern Time).

influenza dioxin

About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture
and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs)
used to diagnose human diseases and screen donated human blood. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied by any forward-looking statement.

abscesses infectious

, and an equal number in Europe.
The presentation is scheduled to be webcast live and may be accessed through a
link on the investor information section of Gen-Probe's website at
http://www. For more information , go to
http://www.

candidiasis infections

nosocomial nipah

Up to 33% of
women with UTIs develop recurrent infections (>2 per year).

Contact: Ralph Levy President, Osel Inc. 206
Cell : 415-699-0135
Email: rlevy@oselinc . Forward-looking
statements are not guarantees of performance.

infectious candidiasis

trachoma zoonoses

The webcast will be available for 30 days following the
event.

cdsc mycologists

Gen-Probe has more than 20 years of NAT
expertise, and its products are used daily in clinical laboratories and blood
collection centers worldwide.

trachoma h5n1

Gen-Probe to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference

com.

infections sepsis

LACTIN-V
contains a natural human bacterium, Lactobacillus crispatus, which has been
carefully selected based upon detailed scientific findings that demonstrate
its unique ability to colonize the vaginal mucosa and to secrete substances
that inhibit the growth of microbial pathogens.com.

nipah influenza

cdsc epidemiologists

Phone: 408-986 -0012 ext.

Communicable/infectious diseases sites.

prion h5n1

com

We assume no obligation and expressly disclaim
any duty to update any forward-looking statement to reflect events or
circumstances after the date of this press release or to reflect the
occurrence of unanticipated events.

niaid rickettsial

, the
Bacterio -Therapeutics company, announced the initiation of two Phase II
clinical trials of LACTIN-V, one for the treatment of recurrent urinary tract
infection (RUTI), and a second for recurrent bacterial vaginosis (RBV). SAN DIEGO, Gen-Probe Incorporated
(Nasdaq: GPRO) announced today that the Company will present at the Pacific
Growth Equities Life Sciences Growth Conference in San Francisco on
June 7, 2005 at approximately 3:30 p.

rickettsial candidiasis

S. The Company also developed and manufactures the only
FDA-approved blood-screening assay for the simultaneous detection of HIV-1 and
HCV, which is marketed by Chiron Corporation.

Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance are not
historical facts and are forward-looking statements.

spirochetal rickettsial

immunologists h5n1

Osel Initiates Two Phase II Trials for LACTIN-V

SANTA CLARA, Calif.
LACTIN-V, a vaginal capsule containing a natural human bacterial organism,
will be studied in a total of eight centers for RUTI and for RBV under the
clinical direction of Lynn Conrad, MD, University of Tennessee Health Science
Center, Memphis (RUTI), and Benson Horowitz, MD, University of Connecticut
(RBV).S.